Why This 1 Momentum Stock Could Be a Great Addition to Your Portfolio
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Theravance Biopharma ( TBPH ) is a Top-Ranked Growth Stock: Should You Buy?
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Here's Why Shares in Theravance Biopharma Exploded Today
The company is making excellent progress on all its strategic goals.
Theravance's Q3 Earnings Surpass Estimates, Revenues Match
TBPH delivers a third-quarter profit, beating estimates, and 19% revenue growth, fueled by rising collaboration income from Viatris related to Yupelri sales.
Theravance Biopharma ( TBPH ) Q3 Earnings and Revenues Beat Estimates
Theravance Bio (TBPH) delivered earnings and revenue surprises of +233.33% and +2.08%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
VYNE Therapeutics Inc. ( VYNE ) Reports Q3 Loss, Tops Revenue Estimates
VYNE Therapeutics (VYNE) delivered earnings and revenue surprises of +10.53% and +12.67%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
CRMD vs. TBPH: Which Small-Cap Biotech Stock Is the Better Buy?
CorMedix and Theravance take sharply different routes to small-cap biotech growth - one fueled by sales traction, the other by pipeline promise.
PACCAR Posts Downbeat Earnings, Joins Neuphoria Therapeutics, Citius Pharmaceuticals And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session - Coeur Mining ( NYSE:CDE ) , First Majestic Silver ( NYSE:AG )
U.S. stock futures were slightly higher this morning, with the Dow futures gaining around 0.1% on Tuesday. Shares of PACCAR Inc ( NASDAQ:PCAR ) fell 18.3% to $7.64 in pre-market trading after the company posted downbeat third-quarter results.
Why Crown Holdings Shares Are Trading Higher By Around 9%; Here Are 20 Stocks Moving Premarket - Aditxt ( NASDAQ:ADTX ) , Adaptimmune Therapeutics ( NASDAQ:ADAP )
Shares of Crown Holdings Inc ( NYSE:CCK ) rose sharply in pre-market trading after the company reported better-than-expected third-quarter financial results and raised its FY25 adjusted EPS guidance. Crown Holdings reported quarterly adjusted earnings of $2.24 per share, which beat the ...
This Protagonist Therapeutics Analyst Begins Coverage On A Bullish Note; Here Are Top 3 Initiations For Friday - Protagonist Therapeutics ( NASDAQ:PTGX ) , StandardAero ( NYSE:SARO )
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page. B. Riley Securities analyst Mayank Mamtani initiated coverage on Theravance Biopharma, Inc.
Theravance Bio ( TBPH ) Up 9.8% Since Last Earnings Report: Can It Continue?
Theravance Bio (TBPH) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Theravance's Q2 Loss Narrower Than Expected, Revenues Rise Y/Y
TBPH posts better-than-expected second-quarter 2025 results, boosted by Yupelri sales and licensing gains.
Theravance Sales Jump 83 Percent
Theravance Biopharma ( NASDAQ:TBPH ) , a biopharmaceutical company focused on respiratory medicines and rare disease therapeutics, reported its Q2 2025 results on August 12, 2025. The company's revenue ( GAAP ) grew to $26.2 million, slightly ahead of analyst estimates at $25.93 million.
Theravance Biopharma ( TBPH ) Reports Q2 Loss, Tops Revenue Estimates
Theravance Bio (TBPH) delivered earnings and revenue surprises of +42.86% and +53.76%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Akebia Therapeutics ( AKBA ) Reports Break-Even Earnings for Q2
Akebia Therapeutics (AKBA) delivered earnings and revenue surprises of +100.00% and +33.50%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks Industry Outlook Highlights Catalyst Pharmaceuticals, Zevra Therapeutics, Theravance Biopharma, Aldeyra Therapeutics and Larimar Therapeutics
CPRX, ZVRA, TBPH, ALDX, and LRMR shine amid tariff threats, thanks to strong pipelines, demand, and rising earnings estimates.
5 Small Drug Stocks to Buy Amid Trump's New Tariff Threats
Innovation is at its peak in the Zacks Medical-Drugs industry. CPRX, ZVRA, TBPH, ALDX and LRMR may prove to be good additions to one's portfolio.
This Coinbase Global Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday - Artivion ( NYSE:AORT ) , Coinbase Global ( NASDAQ:COIN )
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page. Canaccord Genuity analyst William Plovanic initiated coverage on Artivion, Inc.
TBPH to Sell Remaining Trelegy Royalty Interest to GSK, Stock Rises
Theravance to sell its remaining Trelegy royalty interest to GSK for $225M, with shares jumping 22% on the deal's announcement.
Theravance's Q1 Loss Wider Than Expected, Revenues Rise Y/Y
TBPH reports weaker-than-expected first-quarter 2025 results. Collaboration revenues from Viatris rise year over year.
Theravance Biopharma ( TBPH ) Reports Q1 Loss, Misses Revenue Estimates
Theravance Bio (TBPH) delivered earnings and revenue surprises of -54.55% and 4.20%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
Rigel Pharmaceuticals ( RIGL ) Beats Q1 Earnings and Revenue Estimates
Rigel (RIGL) delivered earnings and revenue surprises of 350% and 22.07%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
Why Is Theravance Bio ( TBPH ) Up 0.4% Since Last Earnings Report?
Theravance Bio (TBPH) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Healthy Returns: Wegovy is linked to an increased risk of hair loss, study suggests
Novo Nordisk's weight loss drug Wegovy is linked to an increased risk of hair loss, a study suggests. Meanwhile, Dexcom received a warning letter from FDA.
Theravance's Q4 Loss In Line With Estimates, Sales Beat
TBPH's fourth-quarter earnings match estimates while sales beat the same marginally. Increased collaboration revenues from Viatris drive revenues higher.
Theravance Biopharma ( TBPH ) Reports Q4 Loss, Tops Revenue Estimates
Theravance Bio (TBPH) delivered earnings and revenue surprises of 0% and 3.50%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?
Lycia Therapeutics Announces the Appointment of Chin Lee, MD, MPH, as Chief Medical Officer and Reveals Immunology Pipeline
SOUTH SAN FRANCISCO, Calif., Feb. 11, 2025 ( GLOBE NEWSWIRE ) -- Lycia Therapeutics, Inc., a biotechnology company developing lysosomal targeting chimera ( LYTAC ) -based protein degradation therapies to eliminate disease at its source, today announced the appointment of Chin Lee, M.D., M.P.H., ...
Lycia Therapeutics Announces the Appointment of Chin Lee, MD, MPH, as Chief Medical Officer and Reveals Immunology Pipeline - Allakos ( NASDAQ:ALLK )
SOUTH SAN FRANCISCO, Calif., Feb. 11, 2025 ( GLOBE NEWSWIRE ) -- Lycia Therapeutics, Inc., a biotechnology company developing lysosomal targeting chimera ( LYTAC ) -based protein degradation therapies to eliminate disease at its source, today announced the appointment of Chin Lee, M.D., M.P.H., ...
Theravance Bio ( TBPH ) Soars 8.3%: Is Further Upside Left in the Stock?
Theravance Bio (TBPH) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Theravance Bio ( TBPH ) Up 3.7% Since Last Earnings Report: Can It Continue?
Theravance Bio (TBPH) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Theravance's Q3 Loss Narrower Than Expected, Revenues Rise Y/Y
TBPH beats third-quarter estimates for both sales and earnings. Increased collaboration revenues from Viatris drive year-over-year top-line performance.
Theravance Biopharma ( TBPH ) Reports Q3 Loss, Tops Revenue Estimates
Theravance Bio (TBPH) delivered earnings and revenue surprises of 40% and 4.71%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?
Will These 5 Biotech Stocks Surpass Q3 Earnings Forecasts?
Let's look at five biotech and drug companies, AZN, NVAX, AXSM, TBPH and PRTA, slated to release their third-quarter 2024 results this week.
Zacks Industry Outlook Madrigal, Corcept, Catalyst Larimar and Theravance
Madrigal, Corcept, Catalyst Larimar and Theravance have been highlighted in this Industry Outlook article.
5 Small Drug Stocks to Buy as Trump Gets Re-Elected
Innovation is at its peak for the Zacks Medical-Drugs industry. MDGL, CORT, CPRX, LRMR and TBPH may prove to be good additions to one's portfolio.
PTC Therapeutics ( PTCT ) Reports Q3 Loss, Tops Revenue Estimates
PTC Therapeutics (PTCT) delivered earnings and revenue surprises of 9.74% and 13.41%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?
Karyopharm Therapeutics ( KPTI ) Reports Q3 Loss, Tops Revenue Estimates
Karyopharm Therapeutics (KPTI) delivered earnings and revenue surprises of 3.70% and 2.43%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?
Why Is Madrigal ( MDGL ) Up 1% Since Last Earnings Report?
Madrigal (MDGL) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Theravance Bio ( TBPH ) Up 2.2% Since Last Earnings Report: Can It Continue?
Theravance Bio (TBPH) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Theravance Q2 Loss Wider Than Expected, Revenues Rise Y/Y - Repare Therapeutics ( NASDAQ:RPTX ) , Halozyme Therapeutics ( NASDAQ:HALO )
Theravance Biopharma, Inc. TBPH reported a second-quarter 2024 adjusted net loss of 13 cents per share, which was wider than the Zacks Consensus Estimate of a loss of 9 cents per share. In the year-ago quarter, the company had reported a loss of 13 cents per share.
Theravance ( TBPH ) Q2 Loss Wider Than Expected, Revenues Rise Y/Y
Theravance (TBPH) misses second-quarter estimates on both fronts. Increased collaboration revenues from Viatris drive year-over-year top-line performance.
Theravance Biopharma ( TBPH ) Reports Q2 Loss, Lags Revenue Estimates
Theravance Bio (TBPH) delivered earnings and revenue surprises of -44.44% and 9.83%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Best Momentum Stocks to Buy for July 15th
TBPH, HGV, and SPT made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on July 15, 2024.
New Strong Buy Stocks for July 15th
TEF, AY, CQP, TBPH, and VIRC have been added to the Zacks Rank #1 (Strong Buy) List on July 15, 2024.
Theravance Biopharma ( NASDAQ:TBPH ) Upgraded by StockNews.com to Buy
Theravance Biopharma ( NASDAQ:TBPH - Get Free Report ) was upgraded by stock analysts at StockNews.com from a "hold" rating to a "buy" rating in a report released on Thursday.
Theravance Biopharma ( NASDAQ:TBPH ) Upgraded to Buy at StockNews.com
StockNews.com upgraded shares of Theravance Biopharma ( NASDAQ:TBPH - Free Report ) from a hold rating to a buy rating in a research note issued to investors on Thursday. Other research analysts have also issued reports about the company.
AstraZeneca's ( AZN ) Imfinzi Meets Study Goal in Bladder Cancer
Data from a late-stage study shows that treatment with AstraZeneca's (AZN) Imfinzi plus chemotherapy before and after bladder removal surgery improves survival in patients.
Wall Street Analysts Predict a 90.53% Upside in Theravance Bio ( TBPH ) : Here's What You Should Know
The mean of analysts' price targets for Theravance Bio (TBPH) points to a 90.5% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Theravance Biopharma ( NASDAQ:TBPH ) Lowered to "Hold" at StockNews.com
Theravance Biopharma ( NASDAQ:TBPH - Get Free Report ) was downgraded by equities researchers at StockNews.com from a "buy" rating to a "hold" rating in a report issued on Thursday.
Theravance Bio ( TBPH ) Down 6.1% Since Last Earnings Report: Can It Rebound?
Theravance Bio (TBPH) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
